Post-Cystectomy Long-Term Follow-Up Needed Even If No Sign of Bladder Cancer
Recurrence of bladder cancer after radical cystectomy can occur up to 4 years after surgery, a study suggests.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
Repeat TURBT Before RC Does Not Improve Bladder Cancer Outcomes
Study results suggest that tumor debulking does not benefit patients undergoing radical cystectomy.
Cytoreductive Nephrectomy Added to ICI Therapy Ups Survival in mRCC
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced the risk of death by 67%.
Nab-Paclitaxel, Pembrolizumab Combo Active in Advanced Urothelial Cancer
Combination nab-paclitaxel and pembrolizumab demonstrated activity in platinum-refractory or cisplatin-ineligible advanced urothelial cancer.
Overall Cancer Mortality 18% Higher in American Indians/Alaska Natives
Breast and prostate cancer mortality rates were higher in AIAN individuals than in White individuals, despite lower incidence rates.
Chronic Conditions More Likely Among Survivors of Pediatric Wilms Tumor
Survivors of Wilms tumor are more likely than the general population to experience chronic health conditions, a study suggests.
Proteinuria, AKI With New Tyrosine Kinase Inhibitors Characterized
Proteinuria was more frequent with regorafenib than with axitinib.
Researchers Characterize Gut Microbiome of Patients With mRCC and Sarcopenia
Sarcopenic patients with metastatic renal cell carcinoma have distinct bacterial populations that express metabolic pathways associated with a catabolic state.
Live Bacterial Product Improves Outcomes in Metastatic Renal Cell Carcinoma
CBM588, a live bacterial product, improves the efficacy of first-line treatment with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma, a study suggests.
RCC Trials Use “Potentially Excessive” Exclusion Criteria
Renal cell carcinoma trials conducted in the past 10 years used exclusion criteria deemed potentially excessive by ASCO and FCR.
Characteristics of Renal Cell Carcinoma Differ According to Genetic Ancestry
Among patients with renal cell carcinoma, clinical presentation, extent of disease, and germline and somatic alterations differ according to genetic ancestry.
Lenvatinib Plus Pembrolizumab Improves PFS2, OS in Advanced Renal Cell Carcinoma
Second progression-free survival is significantly longer with lenvatinib-pembrolizumab than with sunitinib in patients with advanced renal cell carcinoma.
Intratumoral Vaccination Does Not Appear to Benefit Patients With mRCC
Adding ilixadencel to treatment with sunitinib does not appear to improve outcomes in patients with metastatic renal cell carcinoma undergoing nephrectomy.
RCC With NF2 Mutations Associated With Metastatic Disease, Poor Survival
Renal cell carcinoma patients with NF2 driver mutations often present with metastatic disease and have worse survival outcomes, research suggests.
Immunotherapy Combos Overtake TKI Monotherapy as First-Line Treatment for mRCC
Immunotherapy-based combinations have overtaken TKI monotherapy as the most-used first-line treatment for mRCC in US oncology clinics, a study suggests.
Tivozanib Improves Long-Term PFS in Rel/Ref Metastatic Renal Cell Carcinoma
Tivozanib improves long-term progression-free survival, when compared with sorafenib, in patients with relapsed or refractory metastatic renal cell carcinoma, an analysis suggests.
Health Care Utilization Lower With Pembrolizumab-Axitinib Than With Ipilimumab-Nivolumab
Patients receiving first-line pembrolizumab-axitinib for metastatic renal cell carcinoma have lower health care resource utilization than patients receiving ipilimumab-nivolumab.
RCC Patients Have 10-Fold Higher Risk of End-Stage Renal Disease
The risk for end-stage renal disease is 10 times higher in patients with renal cell carcinoma than in the general population, a study suggests.
AUA Surveillance Guidelines May Improve Metastasis-Free Survival
Following the 2013 AUA guidelines on surveillance after partial nephrectomy can improve metastasis-free survival, a study suggests.
Chemoresection Reduces Need for Surgery in Nonmuscle Invasive Bladder Cancer
Chemoresection with mitomycin reduces the number of required surgical procedures in recurrent nonmuscle invasive bladder cancer, a study suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...